navy-cuv-logo-rgb-1200x628px.png
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
September 30, 2024 19:07 ET | Clinuvel Pharmaceuticals Limited
CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
navy-cuv-logo-rgb-1200x628px.png
Afamelanotide in fair-skinned Parkinson’s patients
June 17, 2024 20:39 ET | Clinuvel Pharmaceuticals Limited
CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
navy-cuv-logo-rgb-1200x628px.png
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
March 28, 2024 04:25 ET | Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
Full Latin without Latin logo.png
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
February 01, 2023 19:14 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV)...
Full Latin without Latin logo.png
CLINUVEL Trial Results Show Drug Reduces DNA Damage
January 15, 2023 18:23 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of...
Vitiligo repigmentation in CUV102 study
CLINUVEL progresses vitiligo treatment program
May 09, 2022 21:33 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide...
CUV801 MRI-FLAIR results
Positive final results in stroke
May 03, 2022 20:24 ET | Clinuvel Pharmaceuticals Limited
 ASX: XETRA-DAX:  Level 1 ADR:CUV UR9 CLVLY  EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
Stroke
CLINUVEL to Trial Innovative Drug in Stroke
October 27, 2020 18:50 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
Figure 2
First patient dosed in SCENESSE® DNA Repair Program
September 15, 2020 03:31 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment Note to editors: CLINUVEL is releasing in-depth infographics and a video...
Figure 1: SCENESSE® connects the dots
CLINUVEL progresses innovative DNA Repair Program
September 10, 2020 03:18 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...